Brian Powl Biography and Net Worth

Insider of Kura Oncology

Brian Powl joined Kura as Chief Commercial Officer in August 2023, with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products. Most recently, he served as Chief Commercial Officer for Fate Therapeutics, where he led the commercialization efforts for the company’s oncology and immunology portfolio. Previously, Mr. Powl was Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies. Earlier in his career, Mr. Powl held positions of increasing responsibility at Celgene Corporation including Vice President, Global Commercial CAR T lead, where he led the commercialization efforts of ABECMA^® and BREYANZI^® and served as the Global Marketing lead for Celgene’s flagship multiple myeloma franchise during the life cycle expansion of REVLIMID^® and POMALYST^®. Mr. Powl holds a BS in Biochemistry from the University of California, San Diego and an MBA in Healthcare Management/Marketing from the Wharton School at the University of Pennsylvania.

What is Brian T. Powl's net worth?: The estimated net worth of Brian T. Powl is at least $1.70 million as of January 27th, 2026. Powl owns 183,275 shares of Kura Oncology stock worth more than $1,697,127 as of March 11th. This net worth approximation does not reflect any other assets that Powl may own. Learn More about Brian T. Powl's net worth.
How old is Brian T. Powl?: Powl is currently 50 years old. There are 5 older executives and no younger executives at Kura Oncology. The oldest executive at Kura Oncology is Ms. Kathleen Ford, Chief Operating Officer, who is 77 years old. Learn More on Brian T. Powl's age.
How do I contact Brian T. Powl?: The corporate mailing address for Powl and other Kura Oncology executives is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. Kura Oncology can also be reached via phone at (858) 500-8800 and via email at [email protected]. Learn More on Brian T. Powl's contact information.
Has Brian T. Powl been buying or selling shares of Kura Oncology?: In the last ninety days, Brian T. Powl has sold $54,262.44 of Kura Oncology stock. Most recently, Brian T. Powl sold 6,414 shares of the business's stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a transaction totalling $54,262.44. Following the completion of the sale, the insider now directly owns 183,275 shares of the company's stock, valued at $1,550,506.50. Learn More on Brian T. Powl's trading history.
Who are Kura Oncology's active insiders?: Kura Oncology's insider roster includes Teresa Bair (Chief Legal Officer), Francis Burrows (Insider), Thomas Doyle (SVP, Finance and Accounting), Kathleen Ford (Chief Operating Officer), Laura Johnson (Director), Mollie Leoni (Chief Medical Officer), Thomas Malley (Director), Brian Powl (Insider), Anthony Praill (CFO), Troy Wilson (President and Chief Executive Officer), and Saiid Zarrabian (Insider). Learn More on Kura Oncology's active insiders.
Are insiders buying or selling shares of Kura Oncology?: In the last twelve months, Kura Oncology insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $410,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 185,586 shares worth more than $1,752,908.02. The most recent insider tranaction occured on January, 27th when COO Kathleen Ford sold 1,813 shares worth more than $15,337.98. Insiders at Kura Oncology own 6.4% of the company. Learn More about insider trades at Kura Oncology.
Information on this page was last updated on 1/27/2026.

Brian T. Powl Insider Trading History at Kura Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/27/2026	Sell	6,414	$8.46	$54,262.44	183,275
11/14/2025	Sell	8,887	$11.18	$99,356.66	139,689
9/29/2025	Sell	8,891	$8.94	$79,485.54	99,676

Brian T. Powl Buying and Selling Activity at Kura Oncology

Kura Oncology Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $9.26

$9.20

$9.60

50 Day Range

MA: $8.71

$7.40

$10.39

2 Week Range

Now: $9.26

$5.41

$12.49

Volume

1,608,270 shs

Average Volume

1,590,089 shs

Market Capitalization

$817.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Brian Powl Biography and Net Worth

What is Brian T. Powl's net worth?

How old is Brian T. Powl?

How do I contact Brian T. Powl?

Has Brian T. Powl been buying or selling shares of Kura Oncology?

Who are Kura Oncology's active insiders?

Are insiders buying or selling shares of Kura Oncology?